1. 2022-LBA-325-ESGO Patients with newly diagnosed ovarian cancer treated with maintenance rucaparib: exploratory biomarker analysis from the phase 3 ATHENA-MONO study (GOG-3020/ENGOT-ov45; NCT03522246). (27th October 2022) Authors: Oaknin, Ana; Kristeleit, Rebecca S; Mahdi, Haider S; Lim, Myong Cheol; de Vivo, Rocco; Salinas, Erin A; Wilson, Michelle K; Liontos, Michalis; Santin, Alessandro D; Provencher, Diane M; Demirkiran, Fuat; Willmott, Lyndsay J; Chudecka-Głaz, Anita M; Herzog, Thomas J; Beiner, Mario E; Copeland, Lar... Journal: International journal of gynecological cancer Issue: Volume 32(2022)Supplement 2 Page Start: A472 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 2022-RA-1276-ESGO Pembrolizumab monotherapy for advanced clear cell gynaecological cancer: phase II PEACOCC trial. (20th October 2022) Authors: Miller, Rowan E; Clamp, Andrew; Gourley, Charlie; Roux, Rene; Hall, Marcia; Devlin, Michael-John; Nirsimloo, Rachel; Kounnis, Valentinos; Hughes, Laura; Counsell, Nicholas; Farrelly, Laura; Kristeleit, Rebecca S Journal: International journal of gynecological cancer Issue: Volume 32(2022)Supplement 2 Page Start: A316 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Antitumor activity of the poly(ADP-ribose) polymerase inhibitor rucaparib as monotherapy in patients with platinum-sensitive, relapsed, BRCA-mutated, high-grade ovarian cancer, and an update on safety. Issue 9 (3rd November 2019) Authors: Kristeleit, Rebecca S; Oaknin, Ana; Ray-Coquard, Isabelle; Leary, Alexandra; Balmaña, Judith; Drew, Yvette; Oza, Amit M; Shapira-Frommer, Ronnie; Domchek, Susan M; Cameron, Terri; Maloney, Lara; Goble, Sandra; Lorusso, Domenica; Ledermann, Jonathan A; McNeish, Iain A Journal: International journal of gynecological cancer Issue: Volume 29:Issue 9(2019) Page Start: 1396 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Antitumor activity of the poly(ADP-ribose) polymerase inhibitor rucaparib as monotherapy in patients with platinum-sensitive, relapsed, BRCA-mutated, high-grade ovarian cancer, and an update on safety. Issue 9 (November 2019) Authors: Kristeleit, Rebecca S; Oaknin, Ana; Ray-Coquard, Isabelle; Leary, Alexandra; Balmaña, Judith; Drew, Yvette; Oza, Amit M; Shapira-Frommer, Ronnie; Domchek, Susan M; Cameron, Terri; Maloney, Lara; Goble, Sandra; Lorusso, Domenica; Ledermann, Jonathan A; McNeish, Iain A Journal: International journal of gynecological cancer Issue: Volume 29:Issue 9(2019) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Early oncology clinical trial design in the era of molecular-targeted agents. (August 2010) Authors: Brunetto, Andre T; Kristeleit, Rebecca S; de Bono, Johann S Journal: Future oncology Issue: Volume 6:Number 8(2010) Page Start: 1339 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Early oncology clinical trial design in the era of molecular-targeted agents. (August 2010) Authors: Brunetto, Andre T; Kristeleit, Rebecca S; de Bono, Johann S Journal: Future oncology Issue: Volume 6:Number 8(2010) Page Start: 1339 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Mainstreamed genetic testing for women with ovarian cancer: first-year experience. Issue 3 (13th March 2018) Authors: Rahman, Belinda; Lanceley, Anne; Kristeleit, Rebecca S; Ledermann, Jonathan A; Lockley, Michelle; McCormack, Mary; Mould, Tim; Side, Lucy Journal: Journal of medical genetics Issue: Volume 56:Issue 3(2019) Page Start: 195 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Phase I/IIa, open-label, multicentre study to evaluate the optimal dosing and safety of ODM-203 in patients with advanced or metastatic solid tumours. Issue 6 (1st December 2020) Authors: Bono, Petri; Massard, Christophe; Peltola, Katriina J; Azaro, Analía; Italiano, Antoine; Kristeleit, Rebecca S; Curigliano, Giuseppe; Lassen, Ulrik; Arkenau, Hendrik-Tobias; Hakulinen, Pasi; Garratt, Chris; Ikonen, Tarja; Mustonen, Mika V J; Rodon, Jordi A Journal: ESMO open Issue: Volume 5:Issue 6(2020) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Phase I/IIa, open-label, multicentre study to evaluate the optimal dosing and safety of ODM-203 in patients with advanced or metastatic solid tumours. Issue 6 (1st December 2020) Authors: Bono, Petri; Massard, Christophe; Peltola, Katriina J; Azaro, Analía; Italiano, Antoine; Kristeleit, Rebecca S; Curigliano, Giuseppe; Lassen, Ulrik; Arkenau, Hendrik-Tobias; Hakulinen, Pasi; Garratt, Chris; Ikonen, Tarja; Mustonen, Mika V J; Rodon, Jordi A Journal: ESMO open Issue: Volume 5:Issue 6(2020) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Phase I/IIa, open-label, multicentre study to evaluate the optimal dosing and safety of ODM-203 in patients with advanced or metastatic solid tumours. Issue 6 (1st December 2020) Authors: Bono, Petri; Massard, Christophe; Peltola, Katriina J; Azaro, Analía; Italiano, Antoine; Kristeleit, Rebecca S; Curigliano, Giuseppe; Lassen, Ulrik; Arkenau, Hendrik-Tobias; Hakulinen, Pasi; Garratt, Chris; Ikonen, Tarja; Mustonen, Mika V J; Rodon, Jordi A Journal: ESMO open Issue: Volume 5:Issue 6(2020) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗